University College London
Latest From University College London
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Emerging Company Profile: ADEL Inc. CEO Seung-Yong Yoon tells Scrip how its anti-tau antibody brings something different to the table in the challenging field of Alzheimer's disease and what's in store for the South Korean bioventure.
While it wants to keep other programs for diseases with larger patient populations in house, MeiraGTx believes J&J offers the global reach to expedite its program in inherited retinal diseases, including three clinical candidates.
Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.